Ajanta Pharma announced the vesting of 4,300 cash-settled Stock Appreciation Rights (SARs) on January 31, 2026. These SARs, granted on January 30, 2025, will be settled in cash based on the closing market price on February 2, 2026. The company also approved the cancellation of 800 employee stock options (ESOPs) due to grantees ceasing employment prior to vesting.
SARs Vesting Approved
Ajanta Pharma’s Nomination and Remuneration Committee has approved the vesting of 4,300 cash-settled Stock Appreciation Rights (SARs), effective January 31, 2026. These SARs were initially granted on January 30, 2025. The settlement will be in cash, determined by the closing market price of Ajanta Pharma’s equity shares on the stock exchanges on February 2, 2026. Because the SARs are cash-settled, no new equity shares will be issued; therefore, there will be no dilution of existing shareholding.
Cancellation of Employee Stock Options
The company also announced the cancellation of 800 stock options. These options, granted under the Share Based Incentive Plan (SBIP), were cancelled because the respective employees ceased to be employed by Ajanta Pharma before they could vest. These cancelled stock options have been returned to the ESOP pool, making them available for future grants.
Source: BSE
